NeoImmuneTech (950220) Q2 2026 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-I7 as the core pipeline and Endari® commercialized in North America.

• Achieved first commercial sales of Endari® in the US in May 2026, expanding revenue streams.

• Maintains a dual business model: innovative drug development and commercial product sales.

Financial highlights

• 1H 2026 revenue: $1.15M, up from $66.7K in 2025 and $124.9K in 2024, driven by Endari® sales.

• Operating loss for 1H 2026: $(7.08)M, improved from $(17.7)M in 2025 and $(29.4)M in 2024.

• Net loss for 1H 2026: $(5.45)M, compared to $(22.4)M in 2025 and $(29.97)M in 2024.

• Cash and equivalents at June 2026: $22.8M, down from $27.1M at end-2025.

• R&D expenses for 1H 2026: $3.89M (34% of sales), down from $11.6M in 2025 and $20.1M in 2024.

Outlook and guidance

• Expects continued revenue growth from Endari® and potential licensing deals for NT-I7.

• Strategic focus on advancing NT-I7 clinical trials and expanding commercial partnerships.